ArriVent BioPharma (AVBP) Expected to Release Quarterly Earnings on Friday

Key Points

• ArriVent BioPharma is expected to report Q2 2026 earnings before market open on Friday, August 14. Analysts forecast a loss of $0.98 per share, compared with the company’s $0.96-per-share loss in the prior quarter, which missed estimates.
• AVBP opened at $31.01, with a market capitalization of approximately $1.44 billion and a 52-week trading range of $16.10 to $35.83. Institutional investors currently own 9.48% of the stock.
• Wall Street’s outlook remains generally positive: the stock has a consensus rating of “Moderate Buy” and an average price target of $44.83, despite ratings ranging from Strong Buy to Sell.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) is expected to be issuing its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to post earnings of ($0.98) per share for the quarter. Individuals may visit the the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.08). On average, analysts expect ArriVent BioPharma to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Stock Performance

AVBP opened at $31.01 on Friday. ArriVent BioPharma has a fifty-two week low of $16.10 and a fifty-two week high of $35.83. The firm has a 50-day moving average of $31.79 and a 200 day moving average of $27.53. The firm has a market cap of $1.44 billion, a P/E ratio of -8.94 and a beta of 1.36.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of ArriVent BioPharma in the 4th quarter valued at $227,000. Invesco Ltd. lifted its stake in ArriVent BioPharma by 12.5% in the fourth quarter. Invesco Ltd. now owns 16,892 shares of the company's stock worth $340,000 after purchasing an additional 1,876 shares during the last quarter. XTX Topco Ltd bought a new stake in ArriVent BioPharma in the fourth quarter worth $528,000. Virtus Investment Advisers LLC boosted its position in ArriVent BioPharma by 126.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,894 shares of the company's stock valued at $219,000 after buying an additional 6,078 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of ArriVent BioPharma by 0.7% during the fourth quarter. Wellington Management Group LLP now owns 82,278 shares of the company's stock valued at $1,655,000 after buying an additional 532 shares during the last quarter. 9.48% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AVBP has been the topic of a number of recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Truist Financial upped their price target on ArriVent BioPharma from $43.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, May 29th. Cantor Fitzgerald reissued an "overweight" rating on shares of ArriVent BioPharma in a report on Friday, May 22nd. Finally, Citigroup lowered their price target on shares of ArriVent BioPharma from $45.00 to $43.00 and set a "buy" rating on the stock in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $44.83.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source